Amgen says Kyprolis doubles progression-free survival vs Velcade

Amgen Inc's Kyprolis helped patients with relapsed multiple myeloma live twice as long before their blood cancer worsened compared to a regimen containing rival drug Velcade, according to an interim analysis announced by the company on Sunday. Kyprolis, the centerpiece of Amgen's nearly $10 billion acquisition of Onyx Pharmaceuticals in 2013, had sales last year of $331 million. Velcade, sold by Takeda Pharmaceutical Co and Johnson & Johnson, had 2014 sales of nearly $3 billion. The interim look showed that patients with relapsed multiple myeloma treated with Kyprolis and chemotherapy drug dexamethasone lived for a median of 18.7 months before their disease worsened, compared with 9.4 months for patients treated with Velcade and dexamethasone.



via Health News Headlines - Yahoo News http://ift.tt/1AZcBFM